Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

OCU410

Other · developed by Ocugen

Phase 3 Most advanced trial
OCGN Developer
1 Registered trials

What is OCU410?

OCU410 is an investigational drug studied in Dry Age-related Macular Degeneration.

At a glance

Drug type
Other
Therapy area
Ophthalmology
Developer
Ocugen (OCGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07770828 Phase 3 Dry Age-related Macular Degeneration Recruiting OCGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry Age-related Macular Degeneration

More from Ocugen

OCU200 Phase 1 OCU400 Phase 1/2 OCU410ST Phase 2/3

Follow OCGN, the company behind OCU410

See OCGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OCGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.